Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,963 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,963 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Open enrollment, early-phase tilt
Prostate Cancer has 749 registered US clinical trials, 275 of them open to new participants right now, about 37% of the total.
- 275
- recruiting participants now
- 37%
- of trials open to enrollment
- 75
- in Phase 3-4 (later-stage)
- 53
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #4 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 5 of 15
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
M.D. Anderson Cancer Center
NCT06826768
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Yale University
NCT06111781
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
Virginia Commonwealth University
NCT06237179
PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
NYU Langone Health
NCT07184970
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Shehzad Basaria, M.D.
NCT06957691
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
University of Virginia
NCT04465500
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
University of Chicago
NCT05790213
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity
NCT06190899
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
AstraZeneca
NCT07192614
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
University of Michigan Rogel Cancer Center
NCT05965180
Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
Henry Ford Health System
NCT05958082
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT06457919
Rectal Spacers Use in Prostate Cancer Radiation Therapy
Princeton ProCure management
NCT06594887
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Wake Forest University Health Sciences
NCT04337580
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
City of Hope Medical Center
NCT07210086
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06059118
Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
University of California, Davis
NCT06907446
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Weill Medical College of Cornell University
NCT04402151
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Medical College of Wisconsin
NCT07227077
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Stephen Freedland
NCT03824652
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Duke University
NCT07050433
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
NCT05766371
Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
Medical University of South Carolina
NCT07325721
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
M.D. Anderson Cancer Center
NCT05497024
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Thomas Hope
NCT07054346
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Milton S. Hershey Medical Center
NCT06600698
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
SpectraCure AB
NCT06807359
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Cancer Institute (NCI)
NCT05616650
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
M.D. Anderson Cancer Center
NCT06085664
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
NCT07027124
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Amgen
NCT06613100
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
NCT04731844
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
NCT06303713
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
Medical University of South Carolina
NCT05586360
Telmisartan in Prostate Cancer
Tyler J Curiel
NCT06168487
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Washington University School of Medicine
NCT03424850
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
University of Miami
NCT06392295
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Mark Garzotto, MD
NCT03753243
Comprehensive Assessment of Cancer Theranostic Response
AIQ Solutions
NCT06815354
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
NCT05498272
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Ivan de Kouchkovsky, MD
NCT06384222
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
Indiana University
NCT06817668
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
NCT06099093
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
M.D. Anderson Cancer Center
NCT06759701
NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making
Cedars-Sinai Medical Center
NCT05923684
Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
Case Comprehensive Cancer Center
NCT05590624
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT07335796
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
State University of New York at Buffalo
NCT06172283
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
University of Kansas Medical Center
NCT03802851
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Prostate Cancer right now
275 recruiting of 749 indexed (37% open).
Phase mix: 75 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (53 trials), 9 others listed. 50 shown below, recruiting first. #4 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Prostate Cancer?
PlainTrial tracks 749 US clinical trials for Prostate Cancer, of which 275 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Prostate Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.